DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 111JC101; CYT107; Cidofovir; Collection of blood and urine; Cytarabine; Diagnostic Test: Brain MRI; Didanosine; Emtricitabine; Enfuvirtide; Filgrastim; Interferon alfa; Interferon alfa-2b; Interleukin-7; Lariam; MEFLOQUINE; METHYLPREDNISOLONE; Mefloquine; Methylprednisolone; Neurological evaluation; PREDNISOLONE; Pembrolizumab; Prednisolone; Probenecid; PyVST; Recombinant human interleukin-7; Spinal tap; Tenofovir; Tenofovir-Emtricitabine; Teriflunomide; Topotecan; Tysabri; Zalcitabine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01970410 (ClinicalTrials.gov)	October 2013	22/10/2013	Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV	Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? (Sub-study: SWITCH-JCV)	Multiple Sclerosis	Drug: teriflunomide	Providence Health & Services	Multiple Sclerosis Center of Northeastern New York	Recruiting	21 Years	60 Years	All	70	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01970410
(ClinicalTrials.gov)

October 2013

22/10/2013

Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV

Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? (Sub-study: SWITCH-JCV)

Multiple Sclerosis

Drug: teriflunomide

Providence Health & Services

Multiple Sclerosis Center of Northeastern New York

Recruiting

21 Years

60 Years

All

Phase 4

United States